Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19 - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how the probiotic, LGG, affects the microbiome (the microorganisms that live in and on the human body) in people that have household contact with someone that has COVID-19.

LGG is a type of probiotic, which is made of live bacteria that can improve gut health and potentially improve the immune system and prevent infections.

To learn more about this study, please visit us at: https://sites.duke.edu/protectehc/about-our-study/

What is the Condition Being Studied?

COVID-19

Who Can Participate in the Study?

-Children aged 1+ and adults
-Live with someone diagnosed with COVID-19
-Access to e-mail and internet
-Not currently showing signs of COVID-19

Age Group
Adults, Children

What is Involved?

If you choose to join this study you will:
-Be randomized (like flipping a coin) to group 1 or group 2
--Group 1 will take the probiotic LGG (Lactobacillus rhamnosus GG) for 28 days
--Group 2 will take a placebo (harmless pill) for 28 days
-Send in 3 stool samples over 28 days
-Send in 3 nasal samples over 28 days
-Complete online questionnaires over 60 days

Study Details

Full Title
A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00105674
NCT: NCT04399252
Phase
Phase N/A
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698